Impacts of Cilnidipine and Glibenclamide Combination on Lipid Profile and Glycemic Control in Male Diabetic Rats

AbdelRasool, Abeer Mansour and Mahmood, Nada Satea and Mohammad, Shatha Hani (2025) Impacts of Cilnidipine and Glibenclamide Combination on Lipid Profile and Glycemic Control in Male Diabetic Rats. World's Veterinary Journal. 1070 - 1084. ISSN 2322-4568

Text WVJ15(4)1070-1084,2025 (1).pdf - Published Version Download (1MB)

Abstract

Current diabetes therapies frequently do not succeed in achieving target levels for hyperglycemia and dyslipidemia in a considerable number of patients. Glibenclamide is an oral hypoglycemic agent, whereas cilnidipine is a calcium channel blocker, which has been utilized for its additional metabolic benefits beyond its primary effect on blood pressure control. The presented study aimed to evaluate the synergistic effects of cilnidipine and glibenclamide on glycemic response, insulin sensitivity, and lipid profile in alloxan-induced diabetic rats. Forty-eight male rats were allocated into eight groups, each with six rats, including a normal control, a diabetic control, and six diabetic groups. Three groups were treated with oral cilnidipine alone at 1, 5, and 10 mg/kg, respectively, while the other three groups were treated with a combination of cilnidipine and glibenclamide at 2.5 mg/kg, orally. Diabetes was induced through the use of alloxan at a dosage of 100 mg/kg, intraperitoneally. Successful induction of diabetes was confirmed by an increase in blood glucose level over 200 mg/dl. Serum insulin, HOMA-IR, C-peptide, fasting plasma glucose (FPG), and the lipid markers were measured at the end of the treatment on day 28. In assessing the medicines� interactions, the combination index (CI) method was used. The present results indicated that a significant effect was observed with 10 mg/kg of cilnidipine combined with glibenclamide, which lowered glucose levels to 80.10 ± 5.80 mg/dL, increased insulin levels to 13 ± 0.64 mU/L, and raised C-peptide levels to 1.40 ± 0.09 ng/mL, while normalizing HOMA-IR to 2.56 ± 0.45, compared to the diabetic control group. The value of CI indicating a significant synergy was below 1 for FPG, insulin, and C-peptide. However, the combined medication therapy had an opposing effect (CI > 1) on all lipid parameters, including total, lowand high-density cholesterol, and triglycerides. Although it may be beneficial in enhancing glucose metabolism, it is insufficient to resolve the issues associated with diabetic dyslipidemia and should be considered as a part of a mixed treatment regime. © The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article�s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article�s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

Item Type:	Article
Keywords:	Cilnidipine; Glibenclamide; HOMA-IR; Insulin sensitivity; Lipid profile
Subjects:	S Agriculture > SF Animal culture
Divisions:	World's Veterinary Journal (WVJ)
Page Range:	1070 - 1084
Journal or Publication Title:	World's Veterinary Journal
Journal Index:	Scopus
Volume:	15
Number:	4
Publisher:	Scienceline Publication
Identification Number:	https://doi.org/10.54203/scil.2025.wvj109
ISSN:	2322-4568
Depositing User:	Dr. Alireza Sadeghi
URI:	https://eprints.science-line.com/id/eprint/1674

Actions (login required)

View Item